Frazier Life Sciences Management’s RAPT Therapeutics RAPT Stock Holding History

Frazier Life Sciences Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-983,333	Closed	-$33.3M	–	41
2025 Q4	$33.3M	Buy	+983,333	New	+$30.5M	0.89%	25

Frazier Life Sciences Management's RAPT Position: Q1 2026 in Review

Frazier Life Sciences Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 983,333 shares — an estimated $33.3M sold.

Frazier Life Sciences Management first reported a position in RAPT in Q4 2025 and held it in 1 quarter. The position peaked at $33.3M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Frazier Life Sciences Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Frazier Life Sciences Management sold 983,333 RAPT Therapeutics shares in Q1 2026, an estimated $33.3M.
Frazier Life Sciences Management first reported a position in RAPT Therapeutics in Q4 2025 and held it in 1 quarter.
Frazier Life Sciences Management's RAPT Therapeutics position peaked at $33.3M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Frazier Life Sciences Management's 13F filing for Q1 2026, filed 15 May 2026.